News|Articles|January 20, 2016

Abbott’s Compounding Pharmacy Recalls Products

Abbott’s Compounding Pharmacy voluntarily recalls sterile products due to lack of sterility assurance.

On Jan. 16, 2016, Abbott’s Compounding Pharmacy announced it was voluntarily recalling all unexpired lots of human and animal sterile compounded products including injectable medications, sterile solutions, eye drops, and eye ointments. The recall is in response to a concern of a lack of sterility assurance after a series of onsite FDA inspections. The recalled products were distributed in California.

The recall is cautionary and the company has not received any reports of adverse events regarding the recalled products as of Jan. 16, 2016. However, because microbial contamination could cause serious effects, the company is advising customers to stop using the products immediately and contact their healthcare provider if they experience problems related to the use of the products. 

Source: FDA


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.